May 8, 2023
Dr. Daniel Karlin, Chief Medical Officer at MindMed, is bringing an updated approach to developing an LSD-based drug to treat anxiety and depression. Instead of developing a psychiatric medicine to be taken every day, MindMed is changing the paradigm to a session-based therapy that uses psychedelic drugs and...
May 8, 2023
Dr. Daniel Karlin, Chief Medical Officer at MindMed, is bringing an updated approach to developing an LSD-based drug to treat anxiety and depression. Instead of developing a psychiatric medicine to be taken every day, MindMed is changing the paradigm to a session-based therapy that uses psychedelic drugs and...
Apr 20, 2023
Joe Tucker, the CEO of Enveric Biosciences, is discovering, developing and testing psychedelic-inspired therapies for the treatment of depression, anxiety, and PTSD. Current treatments target receptors in the brain to increase the concentration of serotonin in the brain by going through classic neurotransmitter...
Apr 20, 2023
Joe Tucker, the CEO of Enveric Biosciences, is discovering, developing and testing psychedelic-inspired therapies for the treatment of depression, anxiety, and PTSD. Current treatments target receptors in the brain to increase the concentration of serotonin in the brain by going through classic neurotransmitter...
Apr 25, 2021
Mary Guillermin, Director of Communications and Senior Pellin Practicioner at the Pellin Institute International and author talks about her book John Guillermin: The Man, The Myth, The Movies a story about her husband the British writer and film director of such films as King Kong, The Towering Inferno, The Blue Max and...